Abstract:We report the development of novel cannabinergic probes that can stabilize the cannabinoid receptors (CBRs) through tight binding interactions. Ligand design involves the introduction of select groups at a judiciously chosen position within the classical hexahydrocannabinol template (monofunctionalized probes). Such groups include the electrophilic isothiocyanato, the photoactivatable azido, and the polar cyano moieties. These groups can also be combined to produce bifunctionalized probes potentially capable of interacting at two distinct sites within the CBR-binding domains. These novel compounds display remarkably high binding affinities for CBRs and are exceptionally potent agonists. A key ligand (27a, AM11245) exhibits exceptionally high potency in both in vitro and in vivo assays and was designated as "megagonist," a property attributed to its tight binding profile. By acting both centrally and peripherally, 27a distinguishes itself from our previously reported "megagonist" AM841, whose functions are restricted to the periphery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02053?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02053</a>.Experimental procedures, spectroscopic, analytical, and physical data for 12a–b, 13a–b, 14a–c, 15a–c, 16a–c, 17a–c, 18a–c, 19a–c, 20a–c, 21a–c, 22a–c, 23a–c, 24a–c, 25a–c, 26a–c, and 27a–c; saturation binding curves using [3H]CP-55,940 for CB1 and CB2 receptors pre-incubated with the 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c; and HPLC traces of 25a, 26c, 27b, and 31c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_001.pdf">PDF</a>).Molecular formula strings and biochemical data of 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

The progress of small molecules against cannabinoid 2 receptor (CB2R)

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Latest Advances in Novel Cannabinoid CB2 Ligands for Drug Abuse and Their Therapeutic Potential

Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024)

Rational drug design of CB2 receptor ligands: from 2012 to 2021

Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products

Crystal Structure of the Human Cannabinoid Receptor CB2

Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs

[Research Progress on Anti-Inflammatory Effects of Plant-Derived Cannabinoid Type 2 Receptor Modulators].

Structural and Functional Insights into Cannabinoid Receptors

The CB2 cannabinoid receptor as a therapeutic target in the central nervous system

New Insights in Cannabinoid Receptor Structure and Signaling

Molecular biology of cannabinoid receptors

Identification of Novel Antagonists Targeting Cannabinoid Receptor 2 Using a Multi-Step Virtual Screening Strategy

Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development

Computational Investigation on the Binding Modes of Rimonabant Analogs with CB1 and CB2

Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists

Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists